What is Wedbush’s Estimate for Replimune Group Q3 Earnings?

Replimune Group, Inc. (NASDAQ:REPL) – Analysts at Wedbush raised their Q3 2025 earnings per share estimates for shares of Replimune Group in a report issued on Tuesday, January 21st. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.63) per share for the quarter, up from their prior forecast of ($0.68). The consensus estimate for Replimune Group’s current full-year earnings is ($2.91) per share. Wedbush also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.91) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($2.37) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.42) EPS and FY2029 earnings at ($0.78) EPS.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07.

A number of other equities analysts have also recently commented on REPL. Jefferies Financial Group lifted their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. HC Wainwright lifted their price objective on shares of Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, BMO Capital Markets increased their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $19.14.

Replimune Group Trading Up 5.6 %

REPL opened at $13.75 on Thursday. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a 50-day moving average of $12.18 and a 200 day moving average of $11.28. The firm has a market cap of $940.78 million, a P/E ratio of -4.51 and a beta of 1.28.

Insider Transactions at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in REPL. American Century Companies Inc. lifted its stake in shares of Replimune Group by 17.6% during the 2nd quarter. American Century Companies Inc. now owns 50,785 shares of the company’s stock worth $457,000 after purchasing an additional 7,587 shares during the last quarter. Hsbc Holdings PLC raised its holdings in Replimune Group by 139.1% in the second quarter. Hsbc Holdings PLC now owns 29,344 shares of the company’s stock worth $253,000 after purchasing an additional 17,072 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Replimune Group during the second quarter valued at about $57,000. Cubist Systematic Strategies LLC lifted its position in Replimune Group by 282.2% during the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after acquiring an additional 53,313 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Replimune Group during the 2nd quarter valued at $443,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.